CUMBERLAND, R.I.--(BUSINESS WIRE)--Neurotech Pharmaceuticals, Inc., a private biotech company focused on developing transformative therapies for chronic eye diseases, announced that the U.S. Food and ...

Encelto, the first FDA-approved treatment for MacTel, is implanted intravitreally during a surgery performed by a qualified ophthalmologist. The Food and Drug Administration (FDA) has approved Encelto ...

The FDA approved revakinagene taroretcel (Encelto) as the first treatment for adults with idiopathic macular telangiectasia (MacTel) type 2, Neurotech Pharmaceuticals announced on Thursday. A rare, ...

John A. Moran Eye Center retinal specialist and researcher Paul S. Bernstein, MD, PhD, diagnosed John Ehrman with a rare eye disease known as Macular Telangiectasia Type 2 (MacTel) in 2014. The ...

For people diagnosed with macular telangiectasia type 2 (MacTel)-a rare and slowly progressing retinal disease-there have been no FDA-approved (or other) treatments to slow or stop vision loss. That ...

The approval of revakinagene taroretcel (Encelto; Neurotech) addresses a significant unmet need for patients with macular telangiectasia type 2 (MacTel), clinical investigator Charles C. Wykoff, MD, ...

For people diagnosed with macular telangiectasia type 2 (MacTel)—a rare and slowly progressing retinal disease—there have been no FDA-approved (or other) treatments to slow or stop vision loss. That ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. KOLOA, Hawaii — In this Healio Video Perspective from ...

The Food and Drug Administration (FDA) has extended the review period for the Biologics License Application (BLA) for NT-501 (revakinagene taroretcel) in the treatment of macular telangiectasia type 2 ...

Charles C. Wykoff, MD, PhD, Retinal Consultants of Texas, spoke to the current state of research on revakinagene taroretcel in macular telangiectasia type 2 (MacTel), as well as the importance of ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. The FDA granted priority review of the biologics license ...

LA JOLLA, CA—For people with macular telangiectasia type 2 (MacTel), an orphan retinal disorder that gradually destroys central vision, there have long been no approved treatment options. But now, a ...